Antifungal susceptibilities of 63 Candida isolates_
| Antifungal agent | Candida | MIC range (μg/mL) | No. (%) of isolates indicated susceptibility category by CBPs | ||
|---|---|---|---|---|---|
| S | S-DD | R | |||
| Fluconazole | C. albicans (32) | 0.06–2 | 32(100) | 0 | 0 |
| C. tropic a H s (14) | 0.06–64 | 13(93) | 0 | 1(7) | |
| C. parapsilosis (12) | 0.125–4 | 12(100) | 0 | 0 | |
| C. glabrata (4) | 0.375–4 | 4(100) | 0 | 0 | |
| C. guilliermondii (1) | 1–1 | 1 (100) | 0 | 0 | |
| Voriconazole | C. albicans (32) | 0.06–2 | 29(91) | 3(9) | 0 |
| C. tropic a I is (14) | 0.03–1 | 11(79) | 2(14) | 1(7) | |
| C. parapsilosis (12) | 0.06–1 | 12(100) | 0 | 0 | |
| C. glabrata (4) | 1–4 | 2(50) | 1(25) | 1(25) | |
| C. guilliermondii (1) | 0.5–0.5 | 1 (100) | 0 | 0 | |
Errors with the E-test and disk diffusion methods compared with broth microdilutions for fluconazole and voriconazole
| Method | Category | Fluconazole by BMD | No. of strains | Total agreement (%) | Voriconazole by BMD | No. of strains | Total agreement (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S | I | R | VME | ME | mE | S | I | R | VME | ME | mE | ||||
| ET | S | 61 | 0 | 0 | 0 | 0 | 1 | 98 | 54 | 2 | 0 | 0 | 0 | 5 | 92 |
| I | 1 | 0 | 0 | 1 | 4 | 2 | |||||||||
| R | 0 | 0 | 1 | 0 | 0 | 0 | |||||||||
| DD | S | 57 | 0 | 0 | 0 | 1 | 4 | 92 | 55 | 1 | 0 | 0 | 0 | 1 | 98 |
| I | 4 | 0 | 0 | 0 | 5 | 0 | |||||||||
| R | 1 | 0 | 1 | 0 | 0 | 2 | |||||||||